USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Eli Lilly Announces Clinical Data for Next-Generation Ovarian Cancer Treatment Sofe-M

Investor's Business Daily +1 ·

LLY Lilly(Eli) & Co
$1273.46 -2.54%
View chart & analysis →
  1. 1Eli Lilly & Co. announced new clinical data on Saturday for its next-generation ovarian cancer treatment, sofetapibat mifepristone (Sofe-M).
  2. 2Eli Lilly recorded an objective response rate of 79.3% among patients with measurable disease today.
  3. 3Eli Lilly achieved a disease control rate of 100% among patients with measurable disease today.

So what's the key point?

Eli Lilly announced test results for a new ovarian cancer treatment. This means 100% of patients successfully achieved disease control.

Source Investor's Business Daily +1 · View original ↗

Related 3-line summaries

Awaiting Federal Reserve interest rate decision and major corporate earnings Schaeffer's Research · 13h agoJ.P. Morgan forecasts China, India, and Brazil weight loss drug market to grow to $22 billion by 2035 Reuters · yesterdayEli Lilly shares hit record high, surpassing Berkshire Hathaway in market cap Investor's Business Daily +1 · 3d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news